We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sandoz, the Swiss pharmaceuticals group poised to become the world's biggest
maker of generic drugs, is seeking to exploit latent tax competition between
Germany, Austria and Switzerland in what could be one of Europe's highest profile
company relocations this year.
Imagenetix, Inc., the developer of Celadrin announced that it has tied up with
Cymbiotics, Inc. and Dr. Reddy's Laboratories Ltd., to launch the product in
India.
YM BioSciences, the cancer product development company, announced it has entered
into a binding agreement, subject to the fulfilment of certain preconditions,
in respect of the purchase of DELEX Therapeutics (Mississauga, Canada), a private
clinical stage biotechnology company developing inhalation delivered fentanyl
products to treat cancer pain, pursuant to which DELEX will become a wholly
owned subsidiary of
The small biotech company, 7TM Pharma, will now enter into a partnering race
with one of the world's largest food giant, Procter & Gamble, about the
development of new drugs for the treatment of peripheral vascular diseases and
coronary vascular disease related to arteriosclerosis, the parties write in
a joint press release.
Government is proactively creating
a conducive environment to enhance investment in pharmaceutical industry with
an objective of affording drugs to people on reasonable prices.
With investment in the life sciences sector reaching new record levels in
Israel, a new survey appears to indicate that drug sector investment is lagging
behind healthcare services and medical equipment.
Hungary's government continues to struggle to turn its cost-cutting drug sector
policy into a reality, with regular health budget overspending prompting many
drugmakers to openly question the sustainability of the country's reimbursement
framework, the National Health Insurance Fund (OEP).
A US-ASEAN meeting has highlighted the growing problem of counterfeit drugs
in Thailand, with US officials calling for harsher penalties to curb the trade.
Pieris Proteolab AG, a biopharmaceutical and protein engineering company has
signed an agreement with the biopharmaceutical unit of Syngenta AG of Basel,
Switzerland, to develop an Anticalin based drug for an indication with high
unmet medical need.